Enanta Pharmaceuticals to Participate in Investor Conferences in September
August 31 2023 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that members of management
will participate in four investor conferences being webcast in
September and provide a business update:
- Wells Fargo Securities Healthcare Conference: Fireside Chat at
2:15 p.m. ET on September 7, 2023
- H.C. Wainwright 25th Annual Global Investment Conference:
Presentation at 4:30 p.m. ET on September 12, 2023
- Baird Global Healthcare Conference: Fireside Chat at 1:25 p.m.
ET on September 13, 2023
- 2023 Cantor Global Healthcare Conference: Fireside Chat at 8:45
a.m. ET on September 26, 2023
A live webcast of each event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcasts will
be available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus
(HBV). Enanta is also conducting research on a single agent
targeting both RSV and human metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com
for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230831535787/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024